Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study2022 · 37 citations
2. 2BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth1999 · 1,340 citations
3. 3Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors2022 · 252 citations
4. 4CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis2022 · 13 citations
5. 5SF1126, a Pan-PI3K Inhibitor Has Superior Preclinical Activity to CAL-101 a PI3K Delta-Specific Inhibitor in Aggressive B-Cell Non-Hodgkin's Lymphoma2011 · 5 citations